Zacks Investment Research·Sep 22, 2026
4 Biotech Stocks With Key Clinical Readouts Expected This FallKOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Vaxcyte is a pre-revenue biotech with no approved products, and its investment case hinges entirely on the success of its pneumococcal conjugate vaccine pipeline. The company's R&D spending has surged 183% from $94.6M in 2024Q1 to $267.9M in 2026Q2, driving ne...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Vaxcyte remains pre-revenue with no product sales, and R&D expenses dominate the cost structure, escalating from $94.6M in 2024Q1 to $267.9M in 2026Q2, while net losses widened to $284.3M in 2026Q2.
Vaxcyte is developing innovative vaccines for infectious diseases, including a promising Group A Streptococcus vaccine candidate currently in Phase 1 trials.
The bull case projects Vaxcyte becoming a dominant player in the vaccine space with potential annual revenues exceeding $5 billion.
Recent Phase 2 results for VAX-31 pneumococcal vaccine show strong potential, positioning the company for future success in the vaccine market.
Trailing total returns as of 10/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$1.97+4.4% vs -$2.06 | — vs $13M |
Q2 2026 May 6, 2026 | -$2.30-29.4% vs -$1.78 | — vs $13M |
Q1 2026 Feb 24, 2026 | -$1.80-17.7% vs -$1.53 | — vs $19M |
Q4 2025 Nov 4, 2025 | -$1.56-22.8% vs -$1.27 | — vs — |
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
California State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 5,915.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,186,622 shares of the company's stock after buying an additional 8,050,522 shares during the quarter. California State Teachers
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 3,549 put options on the company. This is an increase of approximately 52% compared to the typical daily volume of 2,333 put options. Analyst Ratings Changes Several equities analysts have recently issued reports on the
Andrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492. The transaction size represents 2% of the total equity stake held before the filing.
Benchmark PCVX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vaxcyte, Inc. (PCVX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $65.02 | $9.39B | -11.55 | — | — | -25.59% | — | |
| $27.82 | $158.56B | 20.46 | -1.65% | 6.81% | 4.87% | — | |
| $142.40 | $351.69B | 19.56 | 1.18% | 4.78% | 6.59% | — | |
| $46.54 | $93.24B | 12.68 | 4.11% | 14.52% | 24.99% | — | |
| $40.23 | $96.6B | 11.24 | 5.49% | 8.09% | 5.5% | — | |
| $92.06 | $23.13B | -18.25 | 0.2% | -64.02% | -9.13% | — |
Vaxcyte, Inc. (PCVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vaxcyte, Inc. (PCVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 15, 2026·SEC
Jun 23, 2026·SEC
Get notified when PCVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vaxcyte, Inc. (PCVX) stock FAQ — growth, dividends, profitability & financials explained
Vaxcyte, Inc. (PCVX) reported a net loss of $1.06B for fiscal year 2025.
Vaxcyte, Inc. (PCVX) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.
Vaxcyte, Inc. (PCVX) had negative free cash flow of $1.20B in fiscal year 2025, likely due to heavy capital investments.
